PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35544792-7	2022	On Ox-LDL-stimulated HUVECs, KNL significantly inhibited the production of pro-inflammatory mediators such as NO, IL-1beta, iNOS, TNF-alpha and IL-6.	kirenol	29-32	interleukin 1 alpha	Homo sapiens	114-122
33806909-0	2021	Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways.	kirenol	29-36	NFE2 like bZIP transcription factor 2	Rattus norvegicus	107-111
33806909-0	2021	Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways.	kirenol	29-36	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
33806909-9	2021	KRL treatment, with Nrf2 upregulation and activation, accompanied by activation of PI3K/AKT, could prevent the administration of DOX to induce cardiac oxidative stress, remodeling, and other effects.	kirenol	0-3	NFE2 like bZIP transcription factor 2	Rattus norvegicus	20-24
33806909-9	2021	KRL treatment, with Nrf2 upregulation and activation, accompanied by activation of PI3K/AKT, could prevent the administration of DOX to induce cardiac oxidative stress, remodeling, and other effects.	kirenol	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	88-91
35544792-7	2022	On Ox-LDL-stimulated HUVECs, KNL significantly inhibited the production of pro-inflammatory mediators such as NO, IL-1beta, iNOS, TNF-alpha and IL-6.	kirenol	29-32	inositol-3-phosphate synthase 1	Homo sapiens	124-128
35544792-7	2022	On Ox-LDL-stimulated HUVECs, KNL significantly inhibited the production of pro-inflammatory mediators such as NO, IL-1beta, iNOS, TNF-alpha and IL-6.	kirenol	29-32	tumor necrosis factor	Homo sapiens	130-139
35544792-7	2022	On Ox-LDL-stimulated HUVECs, KNL significantly inhibited the production of pro-inflammatory mediators such as NO, IL-1beta, iNOS, TNF-alpha and IL-6.	kirenol	29-32	interleukin 6	Homo sapiens	144-148
33389906-13	2020	Kirenol suppressed the status of serum markers of GC and gastrin, ALP, LDH, and gamma-GT.	kirenol	0-7	gastrin	Rattus norvegicus	57-64
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	interleukin 1 alpha	Mus musculus	41-49
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	tumor necrosis factor	Mus musculus	82-91
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	interleukin 6	Mus musculus	93-97
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	cytochrome c oxidase II, mitochondrial	Mus musculus	99-104
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	nitric oxide synthase 2, inducible	Mus musculus	106-110
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2)	Mus musculus	112-120
35365162-9	2022	Besides, kirenol remarkably decreased IL-1beta-induced degradation of aggrecan and collagen-II.	kirenol	9-16	interleukin 1 alpha	Mus musculus	38-46
35365162-10	2022	Furthermore, kirenol significantly inhibited IL-1beta-induced phosphorylation of PI3K/Akt and NF-kappaB signaling.	kirenol	13-20	interleukin 1 alpha	Mus musculus	45-53
35365162-10	2022	Furthermore, kirenol significantly inhibited IL-1beta-induced phosphorylation of PI3K/Akt and NF-kappaB signaling.	kirenol	13-20	thymoma viral proto-oncogene 1	Mus musculus	86-89
33331091-0	2021	Kirenol inhibited the cell survival and induced apoptosis in human thyroid cancer cells by altering PI3K/AKT and MAP kinase signaling pathways.	kirenol	0-7	AKT serine/threonine kinase 1	Homo sapiens	105-108
33981385-0	2021	Kirenol Inhibits B[a]P-Induced Oxidative Stress and Apoptosis in Endothelial Cells via Modulation of the Nrf2 Signaling Pathway.	kirenol	0-7	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
33152433-0	2021	Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens Makino by inhibiting COX-2 expression and inflammatory cell infiltration.	kirenol	0-7	prostaglandin-endoperoxide synthase 2	Mus musculus	143-148
33126167-0	2021	Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways.	kirenol	0-7	TNF superfamily member 11	Homo sapiens	17-22
33126167-0	2021	Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways.	kirenol	0-7	nuclear factor of activated T cells 1	Homo sapiens	124-130
33126167-0	2021	Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways.	kirenol	0-7	caveolin 1	Homo sapiens	135-140
33844371-7	2021	Results showed that the kirenol treatment enhanced the GSH and reduced MDA in the liver and renal tissues and restored TNF-alpha and IL-6.	kirenol	24-31	tumor necrosis factor	Homo sapiens	119-128
33844371-7	2021	Results showed that the kirenol treatment enhanced the GSH and reduced MDA in the liver and renal tissues and restored TNF-alpha and IL-6.	kirenol	24-31	interleukin 6	Homo sapiens	133-137
33572510-0	2021	Protective Effects of Kirenol against Lipopolysaccharide-Induced Acute Lung Injury through the Modulation of the Proinflammatory NFkappaB Pathway and the AMPK2-/Nrf2-Mediated HO-1/AOE Pathway.	kirenol	22-29	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	129-137
33572510-0	2021	Protective Effects of Kirenol against Lipopolysaccharide-Induced Acute Lung Injury through the Modulation of the Proinflammatory NFkappaB Pathway and the AMPK2-/Nrf2-Mediated HO-1/AOE Pathway.	kirenol	22-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	161-165
33572510-0	2021	Protective Effects of Kirenol against Lipopolysaccharide-Induced Acute Lung Injury through the Modulation of the Proinflammatory NFkappaB Pathway and the AMPK2-/Nrf2-Mediated HO-1/AOE Pathway.	kirenol	22-29	heme oxygenase 1	Mus musculus	175-179
33572510-7	2021	Kirenol significantly inhibited the secretion of cytokines, IL-1beta, IL6, and TNFalpha, into the BALF of the mice with LPS-induced ALI through NFkappaB activation.	kirenol	0-7	interleukin 1 alpha	Mus musculus	60-68
33572510-7	2021	Kirenol significantly inhibited the secretion of cytokines, IL-1beta, IL6, and TNFalpha, into the BALF of the mice with LPS-induced ALI through NFkappaB activation.	kirenol	0-7	interleukin 6	Mus musculus	70-73
33572510-7	2021	Kirenol significantly inhibited the secretion of cytokines, IL-1beta, IL6, and TNFalpha, into the BALF of the mice with LPS-induced ALI through NFkappaB activation.	kirenol	0-7	tumor necrosis factor	Mus musculus	79-87
33572510-7	2021	Kirenol significantly inhibited the secretion of cytokines, IL-1beta, IL6, and TNFalpha, into the BALF of the mice with LPS-induced ALI through NFkappaB activation.	kirenol	0-7	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	144-152
33572510-8	2021	Moreover, kirenol attenuated the downregulation of the antioxidant enzymes, superoxide dismutase, glutathione peroxidase, and catalase that was induced by LPS.	kirenol	10-17	catalase	Mus musculus	126-134
33572510-9	2021	HO-1 expression and the phosphorylation of Nrf2 and AMPK2 were also induced by kirenol.	kirenol	79-86	heme oxygenase 1	Mus musculus	0-4
33572510-9	2021	HO-1 expression and the phosphorylation of Nrf2 and AMPK2 were also induced by kirenol.	kirenol	79-86	nuclear factor, erythroid derived 2, like 2	Mus musculus	43-47
33572510-10	2021	The results indicate that kirenol can be developed as a treatment strategy for ALI, and its effects are induced through the inhibition of the NF-kappaB proinflammatory pathway and promotion of AMPK2/Nrf2-mediated HO-1 and antioxidant enzymes (AOE) activation.	kirenol	26-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
33572510-10	2021	The results indicate that kirenol can be developed as a treatment strategy for ALI, and its effects are induced through the inhibition of the NF-kappaB proinflammatory pathway and promotion of AMPK2/Nrf2-mediated HO-1 and antioxidant enzymes (AOE) activation.	kirenol	26-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	199-203
33572510-10	2021	The results indicate that kirenol can be developed as a treatment strategy for ALI, and its effects are induced through the inhibition of the NF-kappaB proinflammatory pathway and promotion of AMPK2/Nrf2-mediated HO-1 and antioxidant enzymes (AOE) activation.	kirenol	26-33	heme oxygenase 1	Mus musculus	213-217
32544068-0	2020	Effect of kirenol on the interaction between the WNT/beta-Catenin and RUNX2/TCF/LEF1 pathways in fracture healing in vivo.	kirenol	10-17	Wnt family member 3A	Rattus norvegicus	49-52
32544068-0	2020	Effect of kirenol on the interaction between the WNT/beta-Catenin and RUNX2/TCF/LEF1 pathways in fracture healing in vivo.	kirenol	10-17	catenin beta 1	Rattus norvegicus	53-65
32544068-0	2020	Effect of kirenol on the interaction between the WNT/beta-Catenin and RUNX2/TCF/LEF1 pathways in fracture healing in vivo.	kirenol	10-17	RUNX family transcription factor 2	Rattus norvegicus	70-75
32544068-0	2020	Effect of kirenol on the interaction between the WNT/beta-Catenin and RUNX2/TCF/LEF1 pathways in fracture healing in vivo.	kirenol	10-17	lymphoid enhancer binding factor 1	Rattus norvegicus	76-84
32544068-1	2020	OBJECTIVE: This study aimed to determine the effects of a natural diterpenoid, kirenol, on fracture healing in vivo in an experimental rat model of femur fracture and investigate its potential mechanism of action via the Wnt/beta-catenin pathway.	kirenol	79-86	Wnt family member 3A	Rattus norvegicus	221-224
32544068-1	2020	OBJECTIVE: This study aimed to determine the effects of a natural diterpenoid, kirenol, on fracture healing in vivo in an experimental rat model of femur fracture and investigate its potential mechanism of action via the Wnt/beta-catenin pathway.	kirenol	79-86	catenin beta 1	Rattus norvegicus	225-237
32544068-12	2020	CONCLUSION: Kirenol may improve fracture healing in a dose-dependent manner with the early activation of the Wnt/beta-catenin pathway and the activation of the Runx-2 pathway.	kirenol	12-19	Wnt family member 3A	Rattus norvegicus	109-112
32544068-12	2020	CONCLUSION: Kirenol may improve fracture healing in a dose-dependent manner with the early activation of the Wnt/beta-catenin pathway and the activation of the Runx-2 pathway.	kirenol	12-19	catenin beta 1	Rattus norvegicus	113-125
32544068-12	2020	CONCLUSION: Kirenol may improve fracture healing in a dose-dependent manner with the early activation of the Wnt/beta-catenin pathway and the activation of the Runx-2 pathway.	kirenol	12-19	RUNX family transcription factor 2	Rattus norvegicus	160-166
33389906-14	2020	The mRNA expression of thioredoxin, glutaredoxin, NF-kappaB, TNF-alpha, IL-6, PGE2 was downregulated via the kirenol in the MNG-challenged rats.	kirenol	109-116	thioredoxin 1	Rattus norvegicus	23-34
33389906-14	2020	The mRNA expression of thioredoxin, glutaredoxin, NF-kappaB, TNF-alpha, IL-6, PGE2 was downregulated via the kirenol in the MNG-challenged rats.	kirenol	109-116	glutaredoxin	Rattus norvegicus	36-48
33389906-14	2020	The mRNA expression of thioredoxin, glutaredoxin, NF-kappaB, TNF-alpha, IL-6, PGE2 was downregulated via the kirenol in the MNG-challenged rats.	kirenol	109-116	tumor necrosis factor	Rattus norvegicus	61-70
33389906-14	2020	The mRNA expression of thioredoxin, glutaredoxin, NF-kappaB, TNF-alpha, IL-6, PGE2 was downregulated via the kirenol in the MNG-challenged rats.	kirenol	109-116	interleukin 6	Rattus norvegicus	72-76
30880468-3	2019	To address this problem, we constructed a novel anti-tumour nanoparticle platform RBC@BPQDs-DOX/KIR, black phosphorus nanoparticle quantum dots (BPQDs) with one of the chemotherapeutics (doxorubicin, DOX) and an anti-inflammatory traditional Chinese medicine active component (Kirenol, KIR).	kirenol	277-284	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	Homo sapiens	96-99
31907162-0	2019	[Kirenol relieves dextran sulfate sodium-induced ulcerative colitis in mice by inhibiting inflammatory cytokines and inducing CD4+ T lymphocyte apoptosis].	kirenol	1-8	CD4 antigen	Mus musculus	126-129
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	interferon gamma	Mus musculus	64-73
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	interleukin 17A	Mus musculus	75-81
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	interleukin 6	Mus musculus	83-87
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	tumor necrosis factor	Mus musculus	92-101
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	CD4 antigen	Mus musculus	181-184
31730422-7	2019	Kirenol markedly increased adenosine triphosphate production and mitochondrial activity by stimulating the expression of markers of mitochondrial biogenesis and upregulating the AMPK/SIRT1/PGC-1alpha/PPARdelta signaling pathway in L6 myotubes.	kirenol	0-7	sirtuin 1	Mus musculus	183-188
31565849-7	2019	Moreover, in diabetic hearts, oral kirenol significantly attenuated activation of mitogen-activated protein kinase subfamily and nuclear translocation of NF-kappaB and Smad2/3 and decreased phosphorylation of IkappaBalpha and both fibrosis-related and apoptosis-related proteins.	kirenol	35-42	SMAD family member 2	Rattus norvegicus	168-175
31565849-7	2019	Moreover, in diabetic hearts, oral kirenol significantly attenuated activation of mitogen-activated protein kinase subfamily and nuclear translocation of NF-kappaB and Smad2/3 and decreased phosphorylation of IkappaBalpha and both fibrosis-related and apoptosis-related proteins.	kirenol	35-42	NFKB inhibitor alpha	Rattus norvegicus	209-221
31565849-8	2019	In an Electrophoretic mobility shift assay, the binding activities of NF-kappaB, Smad3/4, SP1 and AP-1 in the nucleus of diabetic myocardium were significantly down-regulated by kirenol treatment.	kirenol	178-185	SMAD family member 3	Rattus norvegicus	81-88
31565849-8	2019	In an Electrophoretic mobility shift assay, the binding activities of NF-kappaB, Smad3/4, SP1 and AP-1 in the nucleus of diabetic myocardium were significantly down-regulated by kirenol treatment.	kirenol	178-185	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	98-102
31730422-7	2019	Kirenol markedly increased adenosine triphosphate production and mitochondrial activity by stimulating the expression of markers of mitochondrial biogenesis and upregulating the AMPK/SIRT1/PGC-1alpha/PPARdelta signaling pathway in L6 myotubes.	kirenol	0-7	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	189-199
31730422-7	2019	Kirenol markedly increased adenosine triphosphate production and mitochondrial activity by stimulating the expression of markers of mitochondrial biogenesis and upregulating the AMPK/SIRT1/PGC-1alpha/PPARdelta signaling pathway in L6 myotubes.	kirenol	0-7	peroxisome proliferator activator receptor delta	Mus musculus	200-209
27880964-4	2017	In Hs68 fibroblasts, kirenol also significantly suppressed MMP expression while increasing the expression of COL1A1, COL3A1, and COL7A1.	kirenol	21-28	collagen, type I, alpha 1	Mus musculus	109-115
31244849-4	2019	In the present study, we found that Kirenol inhibited the migration, invasion, and proinflammatory of IL-6 secretion of RA-associated synovial fibroblasts (FLS) at a concentration of 100-200 mug/ml in vitro.	kirenol	36-43	interleukin 6	Mus musculus	102-106
27880964-4	2017	In Hs68 fibroblasts, kirenol also significantly suppressed MMP expression while increasing the expression of COL1A1, COL3A1, and COL7A1.	kirenol	21-28	collagen, type III, alpha 1	Mus musculus	117-123
27880964-4	2017	In Hs68 fibroblasts, kirenol also significantly suppressed MMP expression while increasing the expression of COL1A1, COL3A1, and COL7A1.	kirenol	21-28	collagen, type VII, alpha 1	Mus musculus	129-135
25762107-8	2015	Further in vitro studies showed that kirenol inhibited viability of MOG-specific lymphocytes and induced apoptosis of MOG-specific CD4+ T cells in a dose- and time-dependent manner.	kirenol	37-44	myelin oligodendrocyte glycoprotein	Mus musculus	68-71
25762107-8	2015	Further in vitro studies showed that kirenol inhibited viability of MOG-specific lymphocytes and induced apoptosis of MOG-specific CD4+ T cells in a dose- and time-dependent manner.	kirenol	37-44	myelin oligodendrocyte glycoprotein	Mus musculus	118-121
25762107-0	2015	Kirenol attenuates experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells.	kirenol	0-7	negative elongation factor complex member C/D, Th1l	Mus musculus	94-97
25762107-9	2015	Kirenol treatment upregulated Bax,downregulated Bcl-2,and increased activation of caspase-3 and release of cytochrome c, indicating that a mitochondrial pathway was involved in kirenol induced apoptosis.	kirenol	0-7	BCL2-associated X protein	Mus musculus	30-33
25762107-5	2015	Kirenol treatment reduced expression of IFN-gamma and IL-17A in the serum and proportion of Th1 and Th17 cells in draining lymph nodes.	kirenol	0-7	interferon gamma	Mus musculus	40-49
25762107-9	2015	Kirenol treatment upregulated Bax,downregulated Bcl-2,and increased activation of caspase-3 and release of cytochrome c, indicating that a mitochondrial pathway was involved in kirenol induced apoptosis.	kirenol	0-7	B cell leukemia/lymphoma 2	Mus musculus	48-53
25762107-5	2015	Kirenol treatment reduced expression of IFN-gamma and IL-17A in the serum and proportion of Th1 and Th17 cells in draining lymph nodes.	kirenol	0-7	interleukin 17A	Mus musculus	54-60
25762107-5	2015	Kirenol treatment reduced expression of IFN-gamma and IL-17A in the serum and proportion of Th1 and Th17 cells in draining lymph nodes.	kirenol	0-7	negative elongation factor complex member C/D, Th1l	Mus musculus	92-95
25762107-9	2015	Kirenol treatment upregulated Bax,downregulated Bcl-2,and increased activation of caspase-3 and release of cytochrome c, indicating that a mitochondrial pathway was involved in kirenol induced apoptosis.	kirenol	0-7	caspase 3	Mus musculus	82-91
25762107-6	2015	Priming of lymphocytes was reduced and apoptosis of MOG-activated CD4+ T cells was increased in kirenol treated EAE mice.	kirenol	96-103	myelin oligodendrocyte glycoprotein	Mus musculus	52-55
25762107-10	2015	Moreover, pretreatment with either a pan-caspase inhibitor z-VAD-fmk or a more specific caspase 3 inhibitor Ac-DEVD-CHO in lymphocytes reduced kirenol induced apoptosis.	kirenol	143-150	caspase 3	Mus musculus	88-97
24530909-0	2014	Kirenol inhibits adipogenesis through activation of the Wnt/beta-catenin signaling pathway in 3T3-L1 adipocytes.	kirenol	0-7	catenin beta 1	Homo sapiens	60-72
25062891-0	2014	Kirenol stimulates osteoblast differentiation through activation of the BMP and Wnt/beta-catenin signaling pathways in MC3T3-E1 cells.	kirenol	0-7	catenin (cadherin associated protein), beta 1	Mus musculus	84-96
25062891-2	2014	The aim of the present study was to evaluate the effect of kirenol on osteoblast differentiation through activation of the bone morphogenetic protein (BMP) and Wnt/beta-catenin signaling pathways in MC3T3-E1 cells.	kirenol	59-66	catenin (cadherin associated protein), beta 1	Mus musculus	164-176
25062891-4	2014	Kirenol not only increased the expression of osteoblast differentiation markers, such as ALP, type I collagen (ColA1), and osteopontin (OPN), but also increased the expression of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (OPG/RANKL) ratio.	kirenol	0-7	collagen, type I, alpha 1	Mus musculus	111-116
25062891-4	2014	Kirenol not only increased the expression of osteoblast differentiation markers, such as ALP, type I collagen (ColA1), and osteopontin (OPN), but also increased the expression of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (OPG/RANKL) ratio.	kirenol	0-7	secreted phosphoprotein 1	Mus musculus	123-134
25062891-4	2014	Kirenol not only increased the expression of osteoblast differentiation markers, such as ALP, type I collagen (ColA1), and osteopontin (OPN), but also increased the expression of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (OPG/RANKL) ratio.	kirenol	0-7	secreted phosphoprotein 1	Mus musculus	136-139
25062891-4	2014	Kirenol not only increased the expression of osteoblast differentiation markers, such as ALP, type I collagen (ColA1), and osteopontin (OPN), but also increased the expression of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (OPG/RANKL) ratio.	kirenol	0-7	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	248-251
25062891-4	2014	Kirenol not only increased the expression of osteoblast differentiation markers, such as ALP, type I collagen (ColA1), and osteopontin (OPN), but also increased the expression of osteoprotegerin/receptor activator of nuclear factor kappa B ligand (OPG/RANKL) ratio.	kirenol	0-7	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	252-257
25062891-6	2014	In addition, kirenol up-regulated the expression of beta-catenin, CCND1, ALP, and ColA1 which were down-regulated by siRNA knockdown of beta-catenin.	kirenol	13-20	catenin (cadherin associated protein), beta 1	Mus musculus	52-64
25062891-6	2014	In addition, kirenol up-regulated the expression of beta-catenin, CCND1, ALP, and ColA1 which were down-regulated by siRNA knockdown of beta-catenin.	kirenol	13-20	cyclin D1	Mus musculus	66-71
25062891-6	2014	In addition, kirenol up-regulated the expression of beta-catenin, CCND1, ALP, and ColA1 which were down-regulated by siRNA knockdown of beta-catenin.	kirenol	13-20	collagen, type I, alpha 1	Mus musculus	82-87
25062891-6	2014	In addition, kirenol up-regulated the expression of beta-catenin, CCND1, ALP, and ColA1 which were down-regulated by siRNA knockdown of beta-catenin.	kirenol	13-20	catenin (cadherin associated protein), beta 1	Mus musculus	136-148
25062891-7	2014	Overall, these results demonstrate that kirenol is capable of promoting osteoblast differentiation in MC3T3-E1 cells through activation of the BMP and Wnt/beta-catenin signaling pathways, suggesting that it is a potential candidate target for treating or preventing osteoporosis.	kirenol	40-47	catenin (cadherin associated protein), beta 1	Mus musculus	155-167
24530909-2	2014	The present study evaluated the effect of kirenol on anti-adipogenesis through the activation of the Wnt/beta-catenin signaling pathway.	kirenol	42-49	catenin beta 1	Homo sapiens	105-117
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	catenin beta 1	Homo sapiens	38-50
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	LDL receptor related protein 6	Homo sapiens	118-168
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	LDL receptor related protein 6	Homo sapiens	170-174
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	catenin beta 1	Homo sapiens	198-210
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	cyclin D1	Homo sapiens	216-225
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	cyclin D1	Homo sapiens	227-232
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	256-286
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	288-296
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	catenin beta 1	Homo sapiens	38-50
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	LDL receptor related protein 6	Homo sapiens	118-168
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	LDL receptor related protein 6	Homo sapiens	170-174
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	catenin beta 1	Homo sapiens	198-210
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	cyclin D1	Homo sapiens	216-225
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	cyclin D1	Homo sapiens	227-232
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	glycogen synthase kinase 3 beta	Homo sapiens	256-286
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	glycogen synthase kinase 3 beta	Homo sapiens	288-296
24530909-5	2014	Kirenol down-regulated the expression levels of PPARgamma and C/EBPalpha, which were up-regulated by siRNA knockdown of beta-catenin.	kirenol	0-7	peroxisome proliferator activated receptor gamma	Homo sapiens	48-57
24530909-5	2014	Kirenol down-regulated the expression levels of PPARgamma and C/EBPalpha, which were up-regulated by siRNA knockdown of beta-catenin.	kirenol	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	62-72
24530909-5	2014	Kirenol down-regulated the expression levels of PPARgamma and C/EBPalpha, which were up-regulated by siRNA knockdown of beta-catenin.	kirenol	0-7	catenin beta 1	Homo sapiens	120-132
24530909-6	2014	Overall, kirenol is capable of inhibiting the differentiation and lipogenesis of 3T3-L1 adipocytes through the activation of the Wnt/beta-catenin signaling pathway, suggesting its potential as natural anti-obesity agent.	kirenol	9-16	catenin beta 1	Homo sapiens	133-145
24640606-4	2014	Further studies showed that kirenol treatment caused externalization of phosphatidylserine, accumulation of ROS (reactive oxygen species), alteration of mitochondrial membrane potential, release of cytochrome c, reduction in the level of the Bcl-2 protein and upregulation of Bax and tBid, kirenol induced cell apoptosis in a caspase-independent manner.	kirenol	28-35	cytochrome c, somatic	Homo sapiens	198-210
24640606-4	2014	Further studies showed that kirenol treatment caused externalization of phosphatidylserine, accumulation of ROS (reactive oxygen species), alteration of mitochondrial membrane potential, release of cytochrome c, reduction in the level of the Bcl-2 protein and upregulation of Bax and tBid, kirenol induced cell apoptosis in a caspase-independent manner.	kirenol	28-35	BCL2 apoptosis regulator	Homo sapiens	242-247
24640606-4	2014	Further studies showed that kirenol treatment caused externalization of phosphatidylserine, accumulation of ROS (reactive oxygen species), alteration of mitochondrial membrane potential, release of cytochrome c, reduction in the level of the Bcl-2 protein and upregulation of Bax and tBid, kirenol induced cell apoptosis in a caspase-independent manner.	kirenol	28-35	BCL2 associated X, apoptosis regulator	Homo sapiens	276-279
24640606-5	2014	Further studies indicated that kirenol treatment triggered the arrest of cell cycle S period which might resulted from the up-regulation of phosphorylation of p53 (Ser 6 and Ser 37) and expression of p21 protein.	kirenol	31-38	tumor protein p53	Homo sapiens	159-162
24640606-5	2014	Further studies indicated that kirenol treatment triggered the arrest of cell cycle S period which might resulted from the up-regulation of phosphorylation of p53 (Ser 6 and Ser 37) and expression of p21 protein.	kirenol	31-38	H3 histone pseudogene 16	Homo sapiens	200-203
22673798-10	2012	Kirenol also upregulated the mRNA expression of Foxp3, increased the numbers of CD4+CD25+Foxp3+ and IL4+CD4+ T cells, and reduced the number of IFNgamma+CD4+ T cells.	kirenol	0-7	forkhead box P3	Rattus norvegicus	48-53
22673798-10	2012	Kirenol also upregulated the mRNA expression of Foxp3, increased the numbers of CD4+CD25+Foxp3+ and IL4+CD4+ T cells, and reduced the number of IFNgamma+CD4+ T cells.	kirenol	0-7	forkhead box P3	Rattus norvegicus	89-94
22673798-10	2012	Kirenol also upregulated the mRNA expression of Foxp3, increased the numbers of CD4+CD25+Foxp3+ and IL4+CD4+ T cells, and reduced the number of IFNgamma+CD4+ T cells.	kirenol	0-7	interleukin 4	Rattus norvegicus	100-103
22673798-10	2012	Kirenol also upregulated the mRNA expression of Foxp3, increased the numbers of CD4+CD25+Foxp3+ and IL4+CD4+ T cells, and reduced the number of IFNgamma+CD4+ T cells.	kirenol	0-7	interferon gamma	Rattus norvegicus	144-152
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	tumor necrosis factor	Rattus norvegicus	30-39
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interleukin 17A	Rattus norvegicus	41-47
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interleukin 6	Rattus norvegicus	52-56
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	tumor necrosis factor	Rattus norvegicus	79-88
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interleukin 17A	Rattus norvegicus	90-96
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interferon gamma	Rattus norvegicus	101-110
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interleukin 4	Rattus norvegicus	155-159
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	interleukin 10	Rattus norvegicus	161-166
22673798-11	2012	Kirenol reduced the levels of TNF-alpha, IL-17A and IL-6 in synovial fluid and TNF-alpha, IL-17A and IFN-gamma in serum, and increased the serum levels of IL-4, IL-10 and TGF-beta1.	kirenol	0-7	transforming growth factor, beta 1	Rattus norvegicus	171-180
21745559-0	2011	Kirenol upregulates nuclear annexin-1 which interacts with NF-kappaB to attenuate synovial inflammation of collagen-induced arthritis in rats.	kirenol	0-7	annexin A1	Rattus norvegicus	28-37
21745559-9	2011	RESULTS: Kirenol (1, 2, and 4 mg/kg) and prednisolone depressed paw swelling and reduced IL-1beta of synovial fluid in the CIA rats (p<0.05 or p<0.01).	kirenol	9-16	interleukin 1 beta	Rattus norvegicus	89-97
21745559-10	2011	Kirenol and prednisolone upregulated nuclear annexin-1 and inhibited NF-kappaB activity in synovium of CIA.	kirenol	0-7	annexin A1	Rattus norvegicus	45-54
21745559-11	2011	The inhibitory effect of kirenol and prednisolone on NF-kappaB activity was enhanced by anti-annexin-1 Ab.	kirenol	25-32	annexin A1	Rattus norvegicus	93-102
21745559-13	2011	CONCLUSION: Kirenol and prednisolone can upregulate nuclear annexin-1 which interacts with NF-kappaB to inhibit NF-kappaB activity, reduce cytokines expression and thereby attenuate inflammation of CIA joints.	kirenol	12-19	annexin A1	Rattus norvegicus	60-69